• Download mobile app
15 Aug 2020, Edition - 1859, Saturday

Trending Now

  • NCC cadets enthused after PM announces plan for expansion in border, coastal areas
  • Mammoth steps taken to make country self-reliant in defence sector: PM Modi
  • Cricketer Suresh Raina announces international retirement after MS Dhoni bid adieu.
  • Venkaiah Naidu lays foundation stone for housing complex for Rajya Sabha employees
  • Southern leaders are snatched of opportunities by Hindi imposition: Kumaraswamy
  • Non-implementation of PM-Kisan scheme ‘cruel joke’ on Bengal farmers: Governor Dhankhar to Mamata

Businesswire

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer

by businesswireindia.com

Business Wire India
  • Results from a real-world study1 support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology
 

Boehringer Ingelheim announced the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3

 

The addition of nintedanib to docetaxel has a proven survival benefit as a second-line treatment following chemotherapy in a broad population of lung adenocarcinoma patients.4 However, data are scarce regarding the efficacy and safety of nintedanib in adenocarcinoma patients who have been pre-treated with chemotherapy as well as ICIs.

 

The results support a recent update to the ESMO guidelines around the treatment of NSCLC, which now recommend nintedanib in combination with chemotherapy as a second-line treatment following prior chemotherapy +/- ICIs.2 A recent report by Jesus Corral et al (WCLC, 2017) which evaluated nintedanib in combination with docetaxel in a similar setting showed similar efficacy and safety information.3

 

Professor Christian Grohé, Department of Respiratory Diseases, ELK Berlin, said: “As immunotherapy becomes the first-line treatment of choice in advanced lung adenocarcinoma, it’s important to have effective and safe treatment options following immunotherapy. The results from VARGADO provide important evidence supporting the use of nintedanib following initial treatment with immunotherapy and are in line with the recent update to the ESMO guidelines.”

 

Dr Victoria Zazulina, Global Head of Solid Tumour Oncology, Medicine at Boehringer Ingelheim, said: “With a devastating disease like lung cancer, every option matters. Today’s results provide evidence that nintedanib, when added to docetaxel, is a good therapeutic option for patients that progress following treatment with immunotherapy.”

 

~ENDS~

 

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/vargado-data

 

For more information, please visit: www.boehringer-ingelheim.com

 

Further Media Channels

 

www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.youtube.com/user/boehringeringelheim

 

 

 

 
Source: Businesswire
COIMBATORE WEATHER